Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

148 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-09

Study Completion Date

2021-04-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), anticoagulation (warfarin) and antifungal prophylaxis (voriconazole). These are all are associated with known pharmacogenetic interactions, which in some cases render the drugs ineffective or toxic. This could result in negative impacts on quality of life in patients who are already undergoing complicated and costly anticancer regimens. Pharmacogenetic-guided therapy based on an individual patient's genetic profile could potentially target symptoms for which an individual is uniquely susceptible, guiding use of medications that are most likely to be effective, thereby reducing unnecessary physical complications and financial strain. It is hypothesized that patients in the genotype intervention arm will report lower scores for overall symptom distress as compared to patients in the delayed genotype intervention arm following initiation of chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Electronic Patient Reporting of Symptoms During Cancer Treatment

NCT03249090

Metastatic Cancer

COMPLETED NA

The Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Chemotherapy

NCT02574897

Stem Cell Transplantation, Hematopoietic

COMPLETED NA

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725

Cancer

COMPLETED NA

Symptom Management Implementation of Patient Reported Outcomes in Oncology

NCT03850912

Other Cancer Gastrointestinal Cancer Thoracic Cancer +1 more

COMPLETED NA

Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN )

NCT05790538

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, pilot randomized pragmatic clinical trial (PCT) of 500 cancer patients who are undergoing chemotherapy for newly diagnosed or recurrent cancers. Patients will be randomized to genotyping intervention vs delayed genotyping intervention supportive care. Supportive care regimens may include therapies for antiemesis (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), and antifungal prophylaxis (voriconazole), and warfarin depending on their chemotherapy regimen.

For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results. For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice. Both groups will be followed for 3 months and undergo assessments with the MDASI questionnaire four times (pre-chemotherapy, and 2 weeks, 4 weeks and 12 weeks post initiation of chemotherapy.

Records for patients receiving outpatient care at the UF Health Cancer Center clinic at the Medical Plaza will be screened based on inclusion / exclusion criteria for participation in this study. Those that meet criteria will be offered participation. Participation is expected to last approximately 12 weeks and the study will be open for 30-36 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy Supportive Care Genotyping

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a randomized, controlled, parallel arm study.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genotyping Intervention Supportive Care

For those randomized to the genotype intervention group, genotype results will be returned in the EHR pre-emptively and supportive care will be prescribed based on genotype results.

Group Type ACTIVE_COMPARATOR

Genotype-guided Supportive Care

Intervention Type DIAGNOSTIC_TEST

In this arm, supportive care will be administered based on the results of the genotype test.

Delayed Genotyping Intervention Supportive Care

For those randomized to the delayed genotype intervention group, supportive care will be prescribed based on usual clinical practice.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genotype-guided Supportive Care

In this arm, supportive care will be administered based on the results of the genotype test.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have a clinical diagnosis of solid tumor cancer and be seeking treatment and supportive care at the UF Health Cancer Center (Medical Plaza)
* Patients must plan to receive chemotherapy known to be associated with the need for supportive care within 30 days of enrollment
* Life expectancy must be greater than 6 months
* Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Written informed consent obtained from the patient
* The ability for the patient to comply with all the study-related procedures.

Exclusion Criteria

* Patients unwilling or unable to provide voluntary informed consent
* Patients who are unwilling or unable to comply with protocol requirement and/or follow-up procedures
* Patients planned to undergo cancer therapy other than chemotherapy (i.e., radiation, surgery or hormonal treatment alone)
* Prisoners or patients who are involuntarily incarcerated. Patients who are compulsorily detained for treatment of either a psychiatric or physical illness.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No